Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
Moschos
Stergios J
SJ
Kirkwood
John M
JM
Konstantinopoulos
Panagiotis A
PA
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D017024:Chemotherapy, Adjuvant / Q000639:trends; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D016898:Interferon-alpha